FMS vs PEN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
FMS presents a classic deep-value opportunity, characterized by a stable Piotroski F-Score of 6/9 and a current price ($22.77) trading significantly below both its Graham Number ($35.27) and Intrinsic Value ($58.12). While top-line revenue growth is stagnant (-0.30%), the company has demonstrated a massive recovery in earnings and maintains a sustainable dividend payout ratio of 42.76%. The valuation is exceptionally attractive with a Forward P/E of 5.62 and a Price/Book of 0.81. However, the bullish value thesis is countered by a completely bearish technical trend and weak insider sentiment, suggesting a 'value trap' risk if revenue does not stabilize.
Penumbra exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and an exceptionally strong balance sheet characterized by low debt and high liquidity. While the company demonstrates impressive growth metrics, including 38.3% earnings growth and a PEG ratio of 0.74, the current price of $325.33 represents a massive premium over its Graham Number ($60.84) and Intrinsic Value ($133.34). The bullish growth trajectory is currently offset by bearish insider sentiment and a negative technical trend, suggesting the stock may be overextended in the short term.
Compare Another Pair
Related Comparisons
FMS vs PEN: Head-to-Head Comparison
This page compares Fresenius Medical Care AG (FMS) and Penumbra, Inc. (PEN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.